Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

792 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

Tiotropium In Exercise

NCT00525512

Conditions
Behavior, Chronic Disease, Disease Attributes, +8 more
Locations
  • 205.368.01023 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
  • 205.368.01022 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
  • 205.368.01003 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
  • 205.368.01008 Boehringer Ingelheim Investigational Site Fort Collins, Colorado, United States
View all 62 locations
View Trial Details
Completed

Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity

NCT00274573

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Boehringer Ingelheim Investigational Site Aachen, Germany
  • Boehringer Ingelheim Investigational Site Ahrensburg, Germany
  • Boehringer Ingelheim Investigational Site Altenburg, Germany
  • Boehringer Ingelheim Investigational Site Amberg, Germany
View all 177 locations
View Trial Details
Completed

Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients

NCT00620516

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Boehringer Ingelheim Investigational Site 1 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 2 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 3 Busan, South Korea
  • Boehringer Ingelheim Investigational Site 4 Busan, South Korea
View all 71 locations
View Trial Details
Completed

Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00239499

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Tijger Trial Centre Bellville, South Africa
  • Boehringer Ingelheim Investigational Site Bloemfontein, South Africa
  • UCT Lung Institute Cape Town, South Africa
  • Boehringer Ingelheim Investigational Site Cape Town, South Africa
View Trial Details
Completed

Spiriva® Assessment of FEV1 (SAFE)

NCT00277264

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Respiratory Research, Room 1742 Calgary, Alberta, Canada
  • Boehringer Ingelheim Investigational Site Calgary, Alberta, Canada
  • 4A-185, 7007-14 Street SW Calgary, Alberta, Canada
  • Boehringer Ingelheim Investigational Site Edmonton, Alberta, Canada
View all 96 locations
View Trial Details
Completed

Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00274092

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Kaohsiung Veterans General Hospital Kaohsiung City, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Taiwan
  • Veterans General Hospital Taichung, Taiwan
  • National Taiwan University Hospital Taipei, Taiwan
View Trial Details
Completed

A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00144326

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1796 Summer Street Halifax, Nova Scotia, Canada
  • Kingston General Hospital Kingston, Ontario, Canada
  • Respiratory/ Research Lab Toronto, Ontario, Canada
  • Montreal Chest Institute of the Royal Victoria Hospital Montreal, Quebec, Canada
View all 27 locations
View Trial Details
Completed

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00239473

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • Boehringer Ingelheim Investigational Site Berlin, Germany
  • MEDARS GmbH Berlin, Germany
  • Boehringer Ingelheim Investigational Site Bonn, Germany
  • Boehringer Ingelheim Investigational Site Frankfurt am Main, Germany
View all 38 locations
View Trial Details

Related conditions